NO323853B1 - Renset og isolert hamster-EF-1alpha-transkripsjonsregulatorisk DNA, kimaert polynukleotid omfattende dette, vertceller og plasmid omfattende disse og fremgangsmate for okning av transkripsjon av et gen av interesse i en vertcelle - Google Patents

Renset og isolert hamster-EF-1alpha-transkripsjonsregulatorisk DNA, kimaert polynukleotid omfattende dette, vertceller og plasmid omfattende disse og fremgangsmate for okning av transkripsjon av et gen av interesse i en vertcelle Download PDF

Info

Publication number: NO323853B1
Authority: NO; Norway
Prior art keywords: dna; plasmid; seq; gene; fragment
Prior art date: 1997-05-01

Application number

NO19990025A

Other languages

English (en)

Norwegian (no)

Other versions

NO990025D0 (no

NO990025L (no

Inventor

Daniell S Allison

Original Assignee

Icos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-01

Filing date

1999-01-04

Publication date

2007-07-16

1999-01-04 Application filed by Icos Corp filed Critical Icos Corp

1999-01-04 Publication of NO990025D0 publication Critical patent/NO990025D0/no

1999-03-01 Publication of NO990025L publication Critical patent/NO990025L/no

2007-07-16 Publication of NO323853B1 publication Critical patent/NO323853B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 90
230000001105 regulatory effect Effects 0.000 title claims abstract description 65
238000013518 transcription Methods 0.000 title claims abstract description 38
230000035897 transcription Effects 0.000 title claims abstract description 38
241000699800 Cricetinae Species 0.000 title claims abstract description 29
238000000034 method Methods 0.000 title claims abstract description 18
239000013612 plasmid Substances 0.000 title claims description 118
102000040430 polynucleotide Human genes 0.000 title claims description 36
108091033319 polynucleotide Proteins 0.000 title claims description 36
239000002157 polynucleotide Substances 0.000 title claims description 36
108010077524 Peptide Elongation Factor 1 Proteins 0.000 title claims description 24
102000010292 Peptide Elongation Factor 1 Human genes 0.000 title claims description 21
230000002103 transcriptional effect Effects 0.000 title claims description 4
108020004414 DNA Proteins 0.000 claims abstract description 159
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 45
210000004027 cell Anatomy 0.000 claims description 105
102100027377 HBS1-like protein Human genes 0.000 claims description 25
101001009070 Homo sapiens HBS1-like protein Proteins 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 23
239000013598 vector Substances 0.000 claims description 19
239000000872 buffer Substances 0.000 claims description 13
150000007523 nucleic acids Chemical group 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 12
125000003729 nucleotide group Chemical group 0.000 claims description 12
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 9
239000013613 expression plasmid Substances 0.000 claims description 8
241000699802 Cricetulus griseus Species 0.000 claims description 6
210000001672 ovary Anatomy 0.000 claims description 5
108091081024 Start codon Proteins 0.000 claims description 4
230000001737 promoting effect Effects 0.000 claims description 4
230000010354 integration Effects 0.000 claims description 3
230000008685 targeting Effects 0.000 claims 1
230000014509 gene expression Effects 0.000 abstract description 28
239000012634 fragment Substances 0.000 description 136
241000701022 Cytomegalovirus Species 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
230000008488 polyadenylation Effects 0.000 description 15
238000001890 transfection Methods 0.000 description 15
101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 13
108010022394 Threonine synthase Proteins 0.000 description 11
102000004419 dihydrofolate reductase Human genes 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000000047 product Substances 0.000 description 11
229920000936 Agarose Polymers 0.000 description 10
108091092195 Intron Proteins 0.000 description 10
102000006433 Chemokine CCL22 Human genes 0.000 description 9
108010083701 Chemokine CCL22 Proteins 0.000 description 9
238000011144 upstream manufacturing Methods 0.000 description 9
108091026890 Coding region Proteins 0.000 description 8
108020004635 Complementary DNA Proteins 0.000 description 8
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
108010006025 bovine growth hormone Proteins 0.000 description 8
238000010804 cDNA synthesis Methods 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000002609 medium Substances 0.000 description 8
239000000523 sample Substances 0.000 description 8
108700026226 TATA Box Proteins 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
101150074155 DHFR gene Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
102000012286 Chitinases Human genes 0.000 description 5
108010022172 Chitinases Proteins 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000008188 pellet Substances 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
239000006152 selective media Substances 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
102000017143 RNA Polymerase I Human genes 0.000 description 4
108010013845 RNA Polymerase I Proteins 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000013507 mapping Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
108091008324 binding proteins Proteins 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
108020004418 ribosomal RNA Proteins 0.000 description 3
101150116497 sacm1l gene Proteins 0.000 description 3
239000011734 sodium Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
102100024630 Asc-type amino acid transporter 1 Human genes 0.000 description 2
108010024976 Asparaginase Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
102000057361 Pseudogenes Human genes 0.000 description 2
108091008109 Pseudogenes Proteins 0.000 description 2
101150081875 Slc7a10 gene Proteins 0.000 description 2
102000039471 Small Nuclear RNA Human genes 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108020004566 Transfer RNA Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000000137 annealing Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000005026 transcription initiation Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
101100508919 Arabidopsis thaliana IPT6 gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101710151413 Chitinase 1 Proteins 0.000 description 1
101710151415 Chitinase 2 Proteins 0.000 description 1
102100037328 Chitotriosidase-1 Human genes 0.000 description 1
101710132290 Chitotriosidase-1 Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
241000699798 Cricetulus Species 0.000 description 1
241000699679 Cricetulus migratorius Species 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101710107327 Endochitinase 1 Proteins 0.000 description 1
101710107425 Endochitinase 2 Proteins 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
241000276484 Gadus ogac Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
238000012181 QIAquick gel extraction kit Methods 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
101710123428 Ribonuclease pancreatic Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
102000006290 Transcription Factor TFIID Human genes 0.000 description 1
108010083268 Transcription Factor TFIID Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102100030246 Transcription factor Sp1 Human genes 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
239000003990 capacitor Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)

NO19990025A 1997-05-01 1999-01-04 Renset og isolert hamster-EF-1alpha-transkripsjonsregulatorisk DNA, kimaert polynukleotid omfattende dette, vertceller og plasmid omfattende disse og fremgangsmate for okning av transkripsjon av et gen av interesse i en vertcelle NO323853B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/847,218 US5888809A (en)	1997-05-01	1997-05-01	Hamster EF-1α transcriptional regulatory DNA
PCT/US1998/008906 WO1998049289A1 (en)	1997-05-01	1998-05-01	HAMSTER EF-1α TRANSCRIPTIONAL REGULATORY DNA

Publications (3)

Publication Number	Publication Date
NO990025D0 NO990025D0 (no)	1999-01-04
NO990025L NO990025L (no)	1999-03-01
NO323853B1 true NO323853B1 (no)	2007-07-16

Family

ID=25300098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990025A NO323853B1 (no)	1997-05-01	1999-01-04	Renset og isolert hamster-EF-1alpha-transkripsjonsregulatorisk DNA, kimaert polynukleotid omfattende dette, vertceller og plasmid omfattende disse og fremgangsmate for okning av transkripsjon av et gen av interesse i en vertcelle

Country Status (20)

Country	Link
US (1)	US5888809A (da)
EP (2)	EP0920498B1 (da)
JP (1)	JP2000513948A (da)
CN (2)	CN101570753A (da)
AT (1)	ATE318900T1 (da)
AU (1)	AU742561B2 (da)
BR (1)	BR9804896B1 (da)
CZ (1)	CZ296544B6 (da)
DE (1)	DE69833649T2 (da)
DK (1)	DK0920498T3 (da)
ES (1)	ES2263206T3 (da)
HK (1)	HK1022719A1 (da)
HU (1)	HU225764B1 (da)
IL (1)	IL127897A (da)
NO (1)	NO323853B1 (da)
PL (1)	PL195604B1 (da)
PT (1)	PT920498E (da)
RU (2)	RU2249617C2 (da)
SK (1)	SK285664B6 (da)
WO (1)	WO1998049289A1 (da)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8183344B2 (en) *	1996-04-24	2012-05-22	University Of Michigan	Inactivation resistant factor VIII
US6479256B1 (en)	1998-03-04	2002-11-12	Icos Corporation	Lectomedin materials and methods
KR20000046969A (ko) *	1998-12-31	2000-07-25	이선경	이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
US20030088061A1 (en) *	2000-10-12	2003-05-08	Staunton Donald E.	Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
AU2002230773A1 (en) *	2000-12-18	2002-07-01	Wyeth	Promoters and recombinant expression constructs
DK1806407T3 (da) *	2001-07-04	2010-08-16	Chromagenics Bv	DNA-sekvenser med anti-repressoraktivitet
DK1513937T3 (da) *	2002-06-14	2011-05-16	Chromagenics Bv	Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
AU2003243059A1 (en) *	2002-06-14	2003-12-31	Chromagenics B.V.	Use of repression blocking sequences in methods for enhancing gene expression
EP1573058B1 (en) *	2002-12-18	2011-09-14	ChromaGenics B.V.	A method for improving protein production
EP1572994B1 (en) *	2002-12-20	2007-02-21	Chromagenics B.V.	Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
US7687233B2 (en)	2003-09-23	2010-03-30	The University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
US8039230B2 (en) *	2004-11-08	2011-10-18	Chromagenics B.V.	Selection of host cells expressing protein at high levels
CN101090968B (zh)	2004-11-08	2011-10-26	科罗迈吉尼科斯公司	高水平表达蛋白质的宿主细胞的选择
US8999667B2 (en) *	2004-11-08	2015-04-07	Chromagenics B.V.	Selection of host cells expressing protein at high levels
PL1809750T3 (pl) *	2004-11-08	2012-08-31	Chromagenics Bv	Selekcja komórki gospodarza eksprymującej białko na wysokich poziomach
US20060195935A1 (en)	2004-11-08	2006-08-31	Chromagenics B.V.	Selection of host cells expressing protein at high levels
EP1819829A1 (en) *	2004-12-08	2007-08-22	ICOS Corporation	Recombinant method for making multimeric proteins
JP2008532544A (ja) *	2005-03-15	2008-08-21	ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル	活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
WO2007008848A2 (en)	2005-07-07	2007-01-18	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2708763T3 (es)	2005-07-07	2019-04-11	Seattle Genetics Inc	Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
AR056138A1 (es)	2005-10-21	2007-09-19	Hoffmann La Roche	Procedimiento para la expresion recombinante de un polipeptido
CN101341252B (zh)	2005-10-28	2011-08-17	弗·哈夫曼-拉罗切有限公司	啮齿动物细胞中的蛋白质表达
ES2503365T5 (es) *	2005-12-21	2017-10-31	Cnj Holdings, Inc	Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
WO2007081336A1 (en) *	2006-01-13	2007-07-19	Five Prime Therapeutics, Inc.	Mammalian vectors for high-level expression of recombinant proteins
ES2543629T3 (es)	2006-05-17	2015-08-20	Hoffmann-La Roche Ag	Células productoras de polipéptidos
EP2520586A1 (en)	2006-06-30	2012-11-07	The Regents of the University of Michigan	Method of producing factor VIII proteins by recombinant methods
US20090203077A1 (en) *	2006-06-30	2009-08-13	The Regents Of The University Of Michigan	Method of producing factor viii proteins by recombinant methods
TW200902544A (en)	2007-03-13	2009-01-16	Hoffmann La Roche	Peptide-complement conjugates
EP1975228A1 (en)	2007-03-28	2008-10-01	Fachhochschule Mannheim	Polynucleotides for enhancing expression of a polynucleotide of interest
CA2683423C (en)	2007-04-26	2020-10-27	Inspiration Biopharmaceuticals, Inc.	Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
LT2167540T (lt) *	2007-06-29	2018-04-25	F. Hoffmann-La Roche Ag	Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
BRPI0818165B8 (pt)	2007-10-12	2021-05-25	Hoffmann La Roche	método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
CA2705486C (en)	2007-11-19	2019-04-02	Celera Corporation	Lung cancer markers and uses thereof
ES2466340T3 (es)	2008-04-24	2014-06-10	Cantab Biopharmaceuticals Patents Limited	Conjugados de Factor IX con semividas extendidas
PL2282773T3 (pl)	2008-05-02	2014-08-29	Seattle Genetics Inc	Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
PL2462237T3 (pl)	2009-08-06	2016-06-30	Cmc Icos Biologics Inc	Sposoby polepszania wyrażania białka rekombinowanego
DK2478107T3 (da)	2009-09-15	2019-01-02	Medimmune Ltd	Celler til transient ekspression og anvendelser deraf
EP2494040B1 (en) *	2009-10-30	2018-08-29	Aptevo BioTherapeutics LLC	Method of producing recombinant vitamin k dependent proteins
EP2339009A1 (en)	2009-12-22	2011-06-29	Sandoz Ag	Cold inducible promoter sequences
SI3178851T1 (sl)	2010-03-31	2020-09-30	Boehringer Inhelheim International Gmbh	Anti-CD40 protitelesa
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
KR101931591B1 (ko)	2010-11-04	2018-12-24	베링거 인겔하임 인터내셔날 게엠베하	항－ｉｌ－２３ 항체
US9631002B2 (en)	2010-12-21	2017-04-25	The University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin K-dependent proteins
US20150158934A1 (en)	2011-09-09	2015-06-11	Ucl Business Plc	Broadly neutralizing vhh against hiv-1
LT2771031T (lt)	2011-10-28	2018-08-27	Prothena Biosciences Limited	Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną
UA115540C2 (uk)	2011-11-16	2017-11-27	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Антитіло до il-36r
BR112014013035A2 (pt)	2011-12-22	2018-10-09	Hoffmann La Roche	métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
RU2756106C2 (ru)	2011-12-22	2021-09-28	Ф. Хоффманн-Ля Рош Аг	Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
CA3149402A1 (en)	2011-12-22	2013-06-27	F. Hoffman-La Roche Ag	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
DK2807188T3 (da)	2012-01-27	2019-10-07	Prothena Biosciences Ltd	Humaniserede antistoffer, der genkender alpha-synuclein
CN108324943B (zh)	2012-02-10	2024-03-08	思进股份有限公司	Cd30+癌症的检测和治疗
JP2015507929A (ja) *	2012-02-14	2015-03-16	ポートラファーマシューティカルズ，インコーポレイテッド	第Ｘａ因子阻害剤に対する組み換え拮抗剤を製作するためのプロセス
CA2871985C (en)	2012-05-03	2023-10-10	Boehringer Ingelheim International Gmbh	Anti-il-23p19 antibodies
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
ES2744903T3 (es)	2012-11-20	2020-02-26	Univ North Carolina Chapel Hill	Métodos y composiciones para proteínas del factor IX modificadas
AU2014248936B2 (en)	2013-03-12	2020-07-09	Cmc Icos Biologics, Inc.	Improved recombinant protein expression using a hybrid CHEF1 promoter
KR102313513B1 (ko)	2013-03-13	2021-10-15	프로테나 바이오사이언시즈 리미티드	Tau 면역치료제
US10513555B2 (en)	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
RU2535871C1 (ru) *	2013-07-10	2014-12-20	Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ")	Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом
WO2015004632A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize iapp
WO2015004633A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015075635A2 (en)	2013-11-19	2015-05-28	Prothena Biosciences Limited	Monitoring immunotherapy of lewy body disease from constipation symptoms
KR20160113715A (ko)	2014-01-31	2016-09-30	베링거 인겔하임 인터내셔날 게엠베하	신규한 항-ｂａｆｆ 항체
PT3116911T (pt)	2014-03-12	2019-09-04	Prothena Biosciences Ltd	Anticorpos anti-mcam e métodos de utilização associados
KR20160131082A (ko)	2014-03-12	2016-11-15	프로테나 바이오사이언시즈 리미티드	Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh)	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017514458A (ja)	2014-03-12	2017-06-08	プロセナバイオサイエンシーズリミテッド	Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
EP3129051A1 (en)	2014-04-08	2017-02-15	Prothena Biosciences Limited	Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP3708679A1 (en)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
TWI718122B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI718121B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI711631B (zh)	2015-01-28	2020-12-01	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
EP3253786A4 (en)	2015-02-06	2018-10-17	The University of North Carolina at Chapel Hill	Optimized human clotting factor viii gene expression cassettes and their use
BR112017018574A2 (pt)	2015-04-14	2018-04-17	Boehringer Ingelheim International Gmbh	métodos para o tratamento de doenças
CN108025066B (zh)	2015-05-12	2022-04-12	Synt免疫公司	人源化亲和力成熟的抗FcRn抗体
CA2998716A1 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
TWI733695B (zh)	2015-09-18	2021-07-21	德商百靈佳殷格翰國際股份有限公司	治療發炎性疾病之方法
US11560418B2 (en)	2015-10-20	2023-01-24	The University Of North Carolina At Chapel Hill	Methods and compositions for modified factor IX fusion proteins
WO2017149513A1 (en)	2016-03-03	2017-09-08	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
JP6728392B2 (ja)	2016-04-15	2020-07-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	炎症性疾患の処置法
EP3448429B1 (en)	2016-04-25	2021-01-13	Syntimmune Inc.	Humanized affinity matured anti-fcrn antibodies
SG11201808434WA (en)	2016-05-02	2018-10-30	Prothena Biosciences Ltd	Antibodies recognizing tau
PT3452507T (pt)	2016-05-02	2022-12-20	Prothena Biosciences Ltd	Imunoterapia anti-tau
CN109415434B (zh)	2016-05-02	2022-12-30	普罗塞纳生物科学有限公司	识别tau的抗体
WO2017208210A1 (en)	2016-06-03	2017-12-07	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
JP7016470B2 (ja)	2016-07-02	2022-02-07	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
EP3478716A2 (en)	2016-07-02	2019-05-08	Prothena Biosciences Limited	Anti-transthyretin antibodies
JP7076711B2 (ja)	2016-07-02	2022-05-30	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
WO2018060239A1 (en)	2016-09-29	2018-04-05	F. Hoffmann-La Roche Ag	Improved method for selecting polypeptide producing cells
EP3848390A1 (en)	2016-10-14	2021-07-14	Boehringer Ingelheim International GmbH	Methods of treating diseases
EP3601350A1 (en)	2017-03-27	2020-02-05	Boehringer Ingelheim International GmbH	Anti il-36r antibodies combination therapy
KR20200030029A (ko)	2017-05-02	2020-03-19	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
US10793634B2 (en)	2017-06-09	2020-10-06	Boehringer Ingelheim International Gmbh	Anti-TrkB antibodies
WO2019064053A1 (en)	2017-09-28	2019-04-04	Prothena Biosciences Limited	DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
AU2019206443A1 (en)	2018-01-10	2020-07-23	Cmc Icos Biologics, Inc.	Bidirectional CHEFl vectors
CN112004826B (zh)	2018-02-05	2024-06-14	自由大学基金会	反向激动性抗us28抗体
WO2019156566A1 (en)	2018-02-12	2019-08-15	Umc Utrecht Holding B.V.	Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019226050A2 (en)	2018-05-24	2019-11-28	Wageningen Universiteit	Novel viral anti-infective reagents
WO2019235923A1 (en)	2018-06-04	2019-12-12	Erasmus University Medical Center Rotterdam	Role for low density lipoprotein receptor-related protein 10 in progressive brain diseases
MX2020013885A (es)	2018-06-29	2021-03-09	Boehringer Ingelheim Int	Anticuerpos anti-cd40 para su uso en el tratamiento de enfermedades autoinmunes.
CN110904127B (zh)	2018-09-18	2024-09-20	瓦赫宁恩研究基金会	非洲猪瘟病毒疫苗
WO2020080941A1 (en)	2018-10-16	2020-04-23	Umc Utrecht Holding B.V.	Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
AU2019386976B2 (en)	2018-11-26	2024-05-30	Forty Seven, Inc.	Humanized antibodies against c-Kit
WO2020130838A2 (en)	2018-12-21	2020-06-25	Qvq Holding B.V.	Antibodies for preventing or treating candidiasis
CA3131531A1 (en)	2019-03-03	2020-09-10	Prothena Biosciences Limited	Antibodies recognizing tau
MX2021010783A (es)	2019-03-08	2021-09-30	Boehringer Ingelheim Int	Formulaciones de anticuerpo anti-il-36r.
CN114173809A (zh)	2019-04-02	2022-03-11	伊缪纯有限公司	免疫刺激组合物及其用途
TWI836069B (zh)	2019-05-09	2024-03-21	德商百靈佳殷格翰國際股份有限公司	抗-sema3a抗體及其用於治療眼或眼部疾病之用途
TW202115112A (zh)	2019-06-27	2021-04-16	德商百靈佳殷格翰國際股份有限公司	抗-angpt2抗體
AU2020355599A1 (en)	2019-09-24	2022-04-07	Boehringer Ingelheim International Gmbh	Anti-NRP1a antibodies and their uses for treating eye or ocular diseases
WO2021242663A1 (en)	2020-05-26	2021-12-02	Boehringer Ingelheim International Gmbh	Anti-pd-1 antibodies
JP2023533458A (ja)	2020-06-24	2023-08-03	プロシーナバイオサイエンシーズリミテッド	ソルチリンを認識する抗体
US20240317868A1 (en)	2021-02-05	2024-09-26	Boehringer Ingelheim International Gmbh	Anti-il1rap antibodies
AR128065A1 (es)	2021-12-22	2024-03-20	Cdr Life Ag	Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
CN114540352A (zh) *	2022-02-16	2022-05-27	艾瑞生命科学技术(常州)有限公司	一种多核苷酸、载体元件及表达载体和宿主细胞及应用
WO2024096735A1 (en)	2022-10-31	2024-05-10	Stichting Amsterdam UMC	Single domain anti-cd169 antibodies
WO2024101989A1 (en)	2022-11-08	2024-05-16	Stichting Amsterdam UMC	Activation inducible antigen receptors for adoptive immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3051411B2 (ja) *	1989-03-14	2000-06-12	持田製薬株式会社	新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) *	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
WO1991009955A1 (en) *	1989-12-22	1991-07-11	Applied Research Systems Ars Holding N.V.	Endogenous gene expression modification with regulatory element
US5650294A (en) *	1990-06-25	1997-07-22	Basf Aktiengesellschaft	Isolated promoter and terminator of elongation factor 1-α
WO1992020808A1 (en) *	1991-05-15	1992-11-26	Cell Genesys, Inc.	Genomic modifications with homologous dna targeting
CA2051085C (en) *	1991-09-10	2001-08-21	Shigekazu Nagata	Expression plasmids
TW402639B (en) *	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery

1997
- 1997-05-01 US US08/847,218 patent/US5888809A/en not_active Expired - Lifetime
1998
- 1998-05-01 CN CNA2008101103936A patent/CN101570753A/zh active Pending
- 1998-05-01 EP EP98920128A patent/EP0920498B1/en not_active Expired - Lifetime
- 1998-05-01 AT AT98920128T patent/ATE318900T1/de active
- 1998-05-01 IL IL12789798A patent/IL127897A/xx not_active IP Right Cessation
- 1998-05-01 RU RU99101788/13A patent/RU2249617C2/ru active
- 1998-05-01 AU AU72770/98A patent/AU742561B2/en not_active Expired
- 1998-05-01 EP EP06003954A patent/EP1676916A1/en not_active Withdrawn
- 1998-05-01 SK SK118-99A patent/SK285664B6/sk not_active IP Right Cessation
- 1998-05-01 CZ CZ0028099A patent/CZ296544B6/cs not_active IP Right Cessation
- 1998-05-01 JP JP10547444A patent/JP2000513948A/ja active Pending
- 1998-05-01 HU HU0004137A patent/HU225764B1/hu unknown
- 1998-05-01 DE DE69833649T patent/DE69833649T2/de not_active Expired - Lifetime
- 1998-05-01 CN CNB988009137A patent/CN100430477C/zh not_active Expired - Lifetime
- 1998-05-01 BR BRPI9804896-1B1A patent/BR9804896B1/pt active IP Right Grant
- 1998-05-01 ES ES98920128T patent/ES2263206T3/es not_active Expired - Lifetime
- 1998-05-01 DK DK98920128T patent/DK0920498T3/da active
- 1998-05-01 PT PT98920128T patent/PT920498E/pt unknown
- 1998-05-01 PL PL98331005A patent/PL195604B1/pl unknown
- 1998-05-01 WO PCT/US1998/008906 patent/WO1998049289A1/en active Application Filing
1999
- 1999-01-04 NO NO19990025A patent/NO323853B1/no not_active IP Right Cessation
2000
- 2000-03-15 HK HK00101582A patent/HK1022719A1/xx not_active IP Right Cessation
2004
- 2004-12-10 RU RU2004136574/13A patent/RU2004136574A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
US5888809A (en)	1999-03-30
HUP0004137A3 (en)	2003-08-28
ES2263206T3 (es)	2006-12-01
RU2249617C2 (ru)	2005-04-10
CZ28099A3 (cs)	2000-02-16
SK11899A3 (en)	2000-05-16
HU225764B1 (en)	2007-08-28
NO990025D0 (no)	1999-01-04
PL195604B1 (pl)	2007-10-31
WO1998049289A1 (en)	1998-11-05
AU742561B2 (en)	2002-01-03
BR9804896B1 (pt)	2013-11-26
NO990025L (no)	1999-03-01
EP0920498B1 (en)	2006-03-01
EP1676916A1 (en)	2006-07-05
DE69833649D1 (de)	2006-04-27
DE69833649T2 (de)	2006-12-28
EP0920498A1 (en)	1999-06-09
RU2004136574A (ru)	2006-05-27
AU7277098A (en)	1998-11-24
HK1022719A1 (en)	2000-08-18
IL127897A (en)	2005-12-18
IL127897A0 (en)	1999-11-30
CZ296544B6 (cs)	2006-04-12
CN1230991A (zh)	1999-10-06
CN100430477C (zh)	2008-11-05
JP2000513948A (ja)	2000-10-24
CN101570753A (zh)	2009-11-04
BR9804896A (pt)	1999-08-31
PL331005A1 (en)	1999-06-21
DK0920498T3 (da)	2006-07-10
HUP0004137A2 (en)	2001-03-28
ATE318900T1 (de)	2006-03-15
PT920498E (pt)	2006-08-31
SK285664B6 (sk)	2007-05-03

Legal Events

Date	Code	Title	Description
2018-05-07	MK1K	Patent expired

Publication	Publication Date	Title
NO323853B1 (no)	2007-07-16	Renset og isolert hamster-EF-1alpha-transkripsjonsregulatorisk DNA, kimaert polynukleotid omfattende dette, vertceller og plasmid omfattende disse og fremgangsmate for okning av transkripsjon av et gen av interesse i en vertcelle
KR102085189B1 (ko)	2020-04-28	일시적인 유전자 발현을 통한 정교한 식물 변형 방법
AU2023270322A1 (en)	2023-12-14	Compositions and methods for modifying genomes
JP5684445B2 (ja)	2015-03-11	部位特異的セリンリコンビナーゼ及びそれらの使用方法
SG182847A1 (en)	2012-08-30	Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
CN101827938A (zh)	2010-09-08	涉及rt1基因、相关的构建体和方法的具有改变的根构造的植物
KR20180084135A (ko)	2018-07-24	감소된 clr2 활성을 갖는 사상 진균에서 단백질을 생산하는 방법
PT1984512T (pt)	2017-03-13	Sistema de expressão génica utilizando excisão-união em insetos
CS267192A3 (en)	1992-12-16	Expression systems
JP2001500009A (ja)	2001-01-09	植物レトロウイルスポリヌクレオチドおよびその使用のための方法
EP1274854B1 (en)	2009-04-08	Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
KR20060052865A (ko)	2006-05-19	비당화 인간의 알파페토프로테인과 이의 생산방법 및 이의용도
BRPI0616533A2 (pt)	2011-06-21	polinucleotìdeo isolado, fragmento de ácido nucléico isolado, construções de dna recombinante, plantas, sementes, células vegetais, tecidos vegetais, método de isolamento de fragmentos de ácidos nucléico, método de mapeamento de variações genéticas, método de cultivo molecular, plantas de milho, métodos de alteração do transporte de nitrogênio das plantas e variantes de hat de plantas alteradas
JP2001515724A (ja)	2001-09-25	分泌されたβ−グルクロニダーゼの微生物遺伝子、遺伝子産物およびそれらの使用
WO2005054463A1 (ja)	2005-06-16	レトロトランスポゾンを用いた哺乳動物のゲノム改変技術の開発
JP2010522549A (ja)	2010-07-08	目的のポリヌクレオチドの発現を増強するためのポリヌクレオチド
Grippo et al.	2002	Cell‐specific transgene expression from a widely transcribed promoter using Cre/lox in mice
KR19990076627A (ko)	1999-10-15	재조합 배큘로바이러스의 제조
JP2003235575A (ja)	2003-08-26	哺乳動物において機能的なトランスポゾン
CA2259145C (en)	2007-08-21	Hamster ef-1.alpha. transcriptional regulatory dna
JP2006262875A (ja)	2006-10-05	鳥類の卵管内でタンパク質を発現させるための遺伝子構築物、およびこれを用いたタンパク質の生産方法
EP1404842A2 (en)	2004-04-07	Perv screening method and use thereof
US20040231006A1 (en)	2004-11-18	Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
JPH05115283A (ja)	1993-05-14	プロテインホスフアターゼ阻害物質−１の遺伝子及びその発現
NZ503901A (en)	2001-08-31	Transgenic avians containing replication-defective retroviral vectors and methods for tissue specific synthesis of protein in eggs laid by the avian or female progeny thereof.